Journal
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Volume 22, Issue 3, Pages 295-301Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNH.0b013e32835ff9cb
Keywords
C3 glomerulopathy; CFHR; complement; eculizumab
Categories
Ask authors/readers for more resources
Purpose of review This review summarizes recent key findings relating to the role of the complement system in renal pathology. Recent findings There is increasing association of genetic variations in complement and complement control proteins with renal disease. Genome-wide association studies have shown that polymorphisms at the complement factor H-related gene locus are associated with susceptibility to IgA nephropathy and systemic lupus erythematosus (SLE). Rare mutations in these genes are associated with familial forms of C3 glomerulopathy. Mutations in other complement genes have been associated with C3 glomerulopathy and hemolytic uremic syndrome. There are now several reports of the use of anti-C5 antibody therapy in renal disease. Preclinical studies have shown the utility of targeted inhibition of C3 activation in models of lupus glomerulonephritis and ischemia reperfusion injury. Summary Complement activation or dysregulation is important in a range of renal pathology and new therapeutic strategies are being developed which may allow rational therapy for these diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available